CMV pp65 Tetramers: Matching the Reagent to the Donor's HLA Allele
One Antigen Carries Most of the Response
Human cytomegalovirus is a β-herpesvirus that spreads widely and then stays latent in healthy individuals. In immunocompromised hosts the virus reactivates. Hematopoietic stem cell transplant and solid organ transplant recipients are the classic risk groups, and reactivation can cause interstitial pneumonia or gastroenteritis.
The genome encodes more than two hundred proteins. One of them dominates T-cell recognition. pp65, also called UL83, is a 65 kDa lower matrix phosphoprotein. It is expressed early and at high abundance during replication. It can also be processed and presented without new viral protein synthesis. Those properties make it the principal target of CMV-specific cytotoxic T lymphocytes, and the basis for any pp65-directed T-cell assay.
Pinning the Epitope to an Allele
T cells only recognize peptide presented by self-MHC. A pp65 assay therefore has to be tied to a defined HLA allele. Kuzushima and colleagues reported the relevant work in Blood in 2001. They screened 83 candidate peptides using algorithm-based prediction, MHC stabilization assays and enzyme-linked immunospot readouts. One dominant CTL epitope emerged: QYDPVAALF, presented by HLA-A*24:02 and corresponding to pp65 residues 341 to 349.
The allele matters epidemiologically. HLA-A*24:02 is carried far more frequently in East Asian populations, including Chinese and Japanese donors, than in European or North American ones. In A*24-positive, CMV-seropositive healthy donors, CD8+ T cells specific for this peptide account for 0.04% to 0.27% of the total CD8+ pool. The response is concentrated, which is exactly what a tetramer reagent needs.
Two Allele Systems in the Catalog
| Allele | Epitope | pp65 residues | Available labels | Donor population |
|---|---|---|---|---|
| HLA-A*02:01 | NLVPMVATV | 495–503 | APC | European and North American cohorts |
| HLA-A*24:02 | QYDPVAALF | 341–349 | PE, APC | East Asian cohorts |
Both reagents answer the same question, but they are not interchangeable. An A*02:01 tetramer will not stain cells from an A*24:02 donor, and the reverse is equally true. HLA typing therefore precedes reagent selection. Serostatus comes next, because a seronegative donor has no expanded pp65-specific memory pool to detect.
How a Tetramer Is Built
The technology was established by Altman and colleagues in 1996. Peptide-MHC monomers are refolded in vitro. A BirA substrate peptide at the C-terminus of the heavy chain is then biotinylated. Biotinylated monomers are combined with fluorophore-conjugated streptavidin at a 4:1 molar ratio, producing a complex that carries four peptide-MHC units.
The design solves an affinity problem. A single peptide-MHC molecule binds its T-cell receptor weakly and dissociates quickly. Four units bound together raise avidity enough for stable staining. Because detection is direct, no in vitro stimulation or expansion is required. Freshly isolated PBMCs can be stained, counted and phenotyped in one step. The same tube can carry CD27, CD45RA and CCR7 to resolve differentiation state. APC is a practical label here, since it is bright and photostable in multicolor panels.
What the Reported Frequencies Tell You
Two independent validation studies frame the expected range. A Chinese group optimized expression of the HLA-A*24:02 heavy chain in E. coli together with the refolding system, then produced tetramers loaded with QYDPVAALF. Their tetramer-positive CTLs represented 0.09% to 0.37% of CD8+ T cells, confirming suitability for Chinese cohorts.
A Japanese group took the functional question further. They stained peptide-stimulated CTL lines with the same A*24:02/pp65 tetramer. Tetramer-positive frequency correlated strongly with interferon-γ production, with r = 0.943 and P < 0.001. That result supports tetramer staining as a surrogate for effector function when intracellular cytokine assays are impractical.
Reading a Tetramer Plot
A tetramer-positive event sits inside the CD3-positive, CD8-positive parent gate, and it usually appears as a discrete cluster rather than a smear. Two features matter when judging a plot. The cluster should sit clear of the negative population as bounded by the fluorescence-minus-one control. Its position should also be stable between donors carrying the same allele.
A cluster that drifts with the negative peak suggests nonspecific binding rather than antigen specificity. Because these reagents are multimeric, they also bind dead cells and Fc receptor-bearing cells avidly. Viability and dump channels remove most of that artifact before the gate is drawn.
Where Allele Coverage Limits a Study
Allele-restricted reagents impose a recruitment constraint. In a Chinese or Japanese cohort, A*24:02 carriers are common enough that a QYDPVAALF tetramer covers a workable fraction of donors. In a European cohort, A*02:01 covers more donors, so the NLVPMVATV reagent carries the study. Mixed cohorts usually need both reagents, with each donor assigned to the system their typing supports. Planning cohort size around allele frequency, rather than around sample availability, prevents a study from ending with too few evaluable donors.
Monitoring Immunity After Transplant
CMV reactivation remains a leading complication after transplant. Serial measurement of pp65-specific CTL frequency in peripheral blood gives three practical readouts. It estimates infection risk. It helps time antiviral intervention. It tracks immune reconstitution after adoptive CTL infusion. A reagent tied to a defined allele and a defined epitope keeps those numbers comparable between visits and between centers.
Product Information
| Cat. No. | Product Name | Allele and Epitope | Label | Purchase |
|---|---|---|---|---|
| UA089025 | UA-MHC HLA-A*0201/NLVPMVATV CMV pp65 Tetramer-APC Labelled | HLA-A*02:01 / NLVPMVATV | APC | |
| UA089106 | UA-MHC HLA-A*24:02/QYDPVAALF CMV pp65 Tetramer-PE Labelled | HLA-A*24:02 / QYDPVAALF | PE | |
| UA089105 | UA-MHC HLA-A*24:02/QYDPVAALF CMV pp65 Tetramer-APC Labelled | HLA-A*24:02 / QYDPVAALF | APC |
Two formats of the same A*24:02 specificity let one specificity occupy two panels, or let PE and APC be compared across instruments. For a single-donor longitudinal study, keep the label constant. Changing fluorophore mid-study introduces a systematic shift that is easy to mistake for biology.
Controls That Keep the Gate Honest
A tetramer gate needs three companions. A viability dye removes dead cells that bind reagents non-specifically. A CD3 and CD8 backbone defines the parent population. A fluorescence-minus-one control sets the tetramer boundary in the channel actually used. Where an irrelevant-peptide tetramer is available, it provides a cleaner negative than an isotype control, because it matches reagent size and valency. Report the denominator explicitly, as a percentage of CD8+ T cells, and state the HLA type of every donor in the cohort.
ANT BIO PTE. LTD. – Empowering Scientific Breakthroughs
ANT BIO PTE. LTD. supplies high-quality reagents and solutions for life science research. Our sub-brands cover the full research workflow: Starter for antibodies and immunological assay kits, UA-Bio for recombinant proteins and drug discovery solutions, and Absin for general reagents and other detection kits. Explore our product portfolio at www.antbioinc.com.